The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://umairvmov042063.dgbloggers.com/39527713/glp-3-retatrutide-a-comparative-analysis